Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.